Chemoradiation therapy using IMRT followed by durvalumab for locally advanced NSCLC: a multicenter prospective single arm study(WJOG12019L)

Chemoradiation therapy using IMRT followed by durvalumab for locally advanced NSCLC: a multicenter prospective single arm study(WJOG12019L) - CRT using IMRT followed by durvalumab

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038366

Enrollment

Registered

2019-10-24

Start date

2019-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Written informed consent 2. 20<= aged <75 years old 3. Histologically or cytologically proven NSCLC 4. Unresectable and curable locally advanced NSCLC (stage III or recurrence after surgery) 5. Cases will receive CRT consisting of platinum doublets using IMRT (54-66Gy) 6. With measurable lesions (RECIST v1.1) 7. PS (ECOG) 0 or 1 8. In recurrent cases after surgery, adjuvant chemotherapy is permitted, but adjuvant RT is not. 9. No history of thoracic RT for any types of cancer, while chemotherapy and hormone therapy are permitted.

Exclusion criteria

Exclusion criteria: 1. Active double cancer 2. Infection which requires systemic antibiotics 3. Obvious interstitial lung disease or pulmonary fibrosis by chest-CT 4. Uncontrolled comorbidities such as diabetes, hypertension, heart failure, arrythmia, thrombo-embolism, psychotic disease, liver cirrhosis, and/or renal failure) 5. HIV-associated disease 6. Prescription of systemic steroids or immunosuppressant

Design outcomes

Primary

Measure	Time frame
Durvalumab induction rate (rate of cases where durvalumab can be introduced within 42 days after CRT completion)	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results